Tony Mok
MD
Li Shu Fan Medical Foundation Professor of Clinical Oncology
👥Biography 个人简介
Tony Mok conducted the landmark IPASS trial that established EGFR mutation-driven treatment selection as the paradigm for NSCLC precision medicine. His work laid the foundation for the entire field of biomarker-driven lung cancer therapy including adjuvant osimertinib. He remains one of the most influential thoracic oncologists globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Tony Mok 的研究动态
Follow Tony Mok's research updates
留下邮箱，当我们发布与 Tony Mok（Chinese University of Hong Kong）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment